MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)
Rusch V, Chaft J, Johnson B, Wistuba I, Kris M, Lee J, Bunn P, Kwiatkowski D, Reckamp K, Finley D, Haura E, Waqar S, Doebele R, Garon E, Blasberg J, Nicholas A, Schulze K, Phan S, Gandhi M, Carbone D. MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3). Journal Of Thoracic Oncology 2018, 13: s369. DOI: 10.1016/j.jtho.2018.08.346.Peer-Reviewed Original ResearchNon-small cell lung cancerResectable non-small cell lung cancerCell lung cancerNeoadjuvant atezolizumabMulticenter studyLung cancerAtezolizumabCancerNeoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
Rusch V, Chaft J, Johnson B, Wistuba I, Kris M, Lee J, Bunn P, Kwiatkowski D, Reckamp K, Finley D, Haura E, Waqar S, Doebele R, Garon E, Blasberg J, Nicholas A, Schulze K, Phan S, Gandhi M, Carbone D. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). Journal Of Clinical Oncology 2018, 36: 8541-8541. DOI: 10.1200/jco.2018.36.15_suppl.8541.Peer-Reviewed Original ResearchNon-small cell lung cancerResectable non-small cell lung cancerCell lung cancerNeoadjuvant atezolizumabMulticenter studyLung cancerAtezolizumabCancer